Member Info for TorquayFan

Hopefully this is not seen as 'scraping the barrel'.

It's sad to see any hopes fail in the treatment of cancer however Merck's trial supporting Keytruda with Lenvima have failed to improve survival in head and neck cancer https://firstwordpharma.com/story/5774306

Plenty of scope to improve the performance of CI with something that does work.

Dracula gIad you are still positive. As for EE, I didn't see 'that' either but never mind - have a nice weekend.

Dracula I read EE's post as suggesting that there WAS plenty going on.

C11. I can understand the raking but I agree very much with your advice to 'kick back, relax'. However, as always, the best advice is sometimes hard to follow. Particularly after 12 years of waiting in my case. ATB

Cleaner that's $1.4 billion I think.

Another week closer to whenever our next news comes . . .

Something (else) to look forward to in a few weeks time - the arrival of our new Business Development Officer. Trusting that all is still on course, it will be interesting to hear who he/she is. Whoever, they need to get to work asap and I hope the long wait WILL prove to be worthwhile.

Quiet here - missing Crumbs early morning wisdoms. GLA

Post recommended Chester. It sure is quiet right now but not for long !

Crikey WF - been fishing the Helford River myself and thus somewhat out of touch for a day or two but now have seen the BBC pics from Maui - just terrible. You have great memories I'm sure but you just got out in time. Good to see you back and holding of course ! ATB

Hello Takestock - Bermuda made a helpful post on this exact subject on 31/7.

"Development timelines are completely up to Genmab as they now effectively own SC129 and may do as they like with it. Having said that, the licensing agreement will likely contain a clause requiring the IP to be returned to Scancell if Genmab decide not to proceed and also allowing Scancell to reclaim the IP after X number of years of inactivity.

The reality is that it's in Genmab's interest to develop its pipeline as quickly and efficiently as possible, not least because the patent clock is ticking and of course Lindy Durrant has confirmed that all seems to be going well."

I think that says it well and answers the point for me. So fingers crossed and all that jazz. ATB

That's great and thanks Cleaner - I'm guessing there are a 100 speakers or more but let's hope there is a meet we like ! ATB

WTP/Violin - which suggests to me that in moribund trading times, just one or 2 buys OR sells might reflect in the SP ? Time for footy !

Bermuda's reply to Oddmoney caught my eye on Monday . . .

If/(when) we get the next tranche of the Genmab deal, (enhancing the prospects of two further wallops), I think this will cause a stir and raise Scancell's profile wider, beyond the Pharma and science watchers). As Prof. Lindy says, 'all seems to be going well'.

Amen to that !

"Development timelines are completely up to Genmab as they now effectively own SC129 and may do as they like with it. Having said that, the licensing agreement will likely contain a clause requiring the IP to be returned to Scancell if Genmab decide not to proceed and also allowing Scancell to reclaim the IP after X number of years of inactivity.

The reality is that it's in Genmab's interest to develop its pipeline as quickly and efficiently as possible, not least because the patent clock is ticking and of course Lindy Durrant has confirmed that all seems to be going well."

Violin I agree with your 20.46 . . .

Consilium have taken over the Scancell mailing list apparently. Today I received an update not related to Scancell, re. Faron Pharmaceuticals. Strangely, I didn't receive an update when Monday's RNS came, but perhaps next time.

Reflecting on that bizarrely incompetent review in the Vox Markets (?) link posted recently - it illustrates for me that Scancell's science is deeper than most observers can go . . . . there is also a long-term weariness with the poor SP which seems to drag on and on whatever good news we do have.

So it's 'wait on' again and tswsut (?).

Nice day all.

Me too EE - I'm hoping (again) that my Euro-millions comes through on Friday.

MMMmmmm

Thanks CC. Yes it's an actual address by Prof. Lindy, (not just talk around a Poster) competing at 11.00 am with 4 others, (including BioNTech on 'Global Health Strategy'). Let's hope it's well attended. An update on SCIB1 and Modi1 at that stage will be eagerly awaited here for sure !

Hi Cleaner. Not sure what you reply to but 2tyke has been on my filter over there from the start. I agree that Vox piece was laughable. ATB

Inanaco 5120 over there :-

"Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "This is an important milestone for the Company as we now have approval to treat patients with Modi-1 monotherapy or in combination with a CPI in four different tumour types either pre- or post-tumour resection. The information extracted from this study will be invaluable in defining the patient population that will benefit the most from our cancer vaccine, Modi-1."

Just remind folks that Ovarian cancer has not gone well with check points ... with very marginal success. Scancell now has approval to use modi1 with checkpoint in 4 indications not 2. Scancell can now approach Big Pharma on that basis.

That resection data is vital to this expansion as projects can be put together with non approved indications with checkpoint".

Sounds good ?

Chester yes - Prof. Lindy spoke well of Genmab's progress and the next tranche of $ will be welcome for sure.

And Krafty thanks - 'full throttle' I like ! And then, Modi1 apart, there's the 'left field' which could be anything.

Thanks to our CEO for today's update - more when you can please

Yes Violin. Another Monday RNS (!) and a further addition for LTH to be excited about. Scancell's catalogue remains impressive. Impossible to know when we will get news for a re-rate. Soon hopefully. Time will tell. ATB

Hello C7 - I see from another post that you have sold up ? Sorry to see that. ATB